2013 Alzheimer's disease facts and figures

  title={2013 Alzheimer's disease facts and figures},
  author={William H. Thies and Laura Bleiler},
  journal={Alzheimer's \& Dementia},

Role of Improved Vascular Health in the Declining Incidence of Dementia

Whereas the overall number of people affected by dementia will continue to increase because of population aging, an individual’s risk of developing dementia by a specific age has decreased by as much as 20% each decade over the past 30 years.

Alzheimer's Disease Clinical and Research Update for Health Care Practitioners

It is necessary for the health practitioner to remain current, regarding AD, as such information will facilitate better care for patients and their families.

Mortality and Productivity Losses From Alzheimer Disease Among US Adults Aged 40 to 64 Years, 1999 to 2010

The extent of the AD mortality burden for decedents aged 40 to 64 years and productivity losses due to premature death from AD have not been extensively studied in the United States.

PET Imaging of Tau Pathology in Alzheimer’s Disease and Tauopathies

There is a call for the development and integration of pathologic biomarkers into routine clinical evaluation to establish revised diagnostic criteria for clinical and preclinical AD and molecular imaging, specifically positron emission tomography (PET), is a promising modality for early detection and disease staging in Alzheimer’s patients.

Health State Values for Use in the Economic Evaluation of Treatments for Alzheimer’s Disease

The literature on health state values in AD is limited and overly reliant on a single symptom (cognition) to describe disease progression, and other approaches to characterizing disease progression in AD based on multiple outcomes or dependency may be better predictors of costs and utilities in economic evaluations.

Bapineuzumab, an investigational agent for Alzheimer's disease.

A clinical diagnosis of AD involves identifying a decline in cognitive functioning and an accompanying decline in the ability to perform independent activities or activities of daily living (ADL), and therapy recommendations include one of the four FDA-approved cholinesterase inhibitors.

Clinical epidemiology of Alzheimer’s disease: assessing sex and gender differences

The differences observed in men versus women in the incidence and prevalence of MCI and AD, in the structure and function of the brain, and in the sex-specific and gender-specific risk and protective factors for AD are discussed.



Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset.

If interventions could delay onset of the disease by 2 years, after 50 years there would be nearly 2 million fewer cases than projected; if onset could be delayed by 1 year, thereWould be nearly 800,000 fewer prevalent cases.

Alzheimer disease in the United States (2010–2050) estimated using the 2010 census

The number of people in the United States with AD dementia will increase dramatically in the next 40 years unless preventive measures are developed.

Annual Incidence of Alzheimer Disease in the United States Projected to the Years 2000 Through 2050

The number of people with Alzheimer disease and the proportion of the total population affected will increase substantially and without progress in preventing or delaying onset of Alzheimer disease is expected to increase substantially.

Alzheimer disease in the US population: prevalence estimates using the 2000 census.

The number of persons with AD in the US population will continue to increase unless new discoveries facilitate prevention of the disease, according to current and future estimates of prevalence of clinically diagnosed AD.

Lifetime risk of dementia and Alzheimer's disease

The actual remaining lifetime risk of AD or dementia varies with age, sex, and life expectancy and is lower than the hypothetical risk estimated by a cumulative incidence in the same population.

Prevalence of Dementia in the United States: The Aging, Demographics, and Memory Study

Dementia prevalence estimates from this first nationally representative population-based study of dementia in the USA to include subjects from all regions of the country can provide essential information for effective planning for the impending healthcare needs of the large and increasing number of individuals at risk for dementia as the population ages.

State-specific projections through 2025 of Alzheimer disease prevalence

Prevalence rates are calculated using AD incidence estimates from a population study of a geographically defined biracial community of Chicago, National Center for Health Statistics data, and state-specific mortality and population projections corresponding to middle-series estimates for the national population for future years.

Dementia and Alzheimer disease incidence: a prospective cohort study.

The authors' dementia and AD incidence rates are consistent with recent US and European cohort studies, providing clinicians and researchers new information concerning the reproducibility of incidence estimates across settings.

Survival following a diagnosis of Alzheimer disease.

The effect of a diagnosis of AD on life span depends crucially on the age of the person when AD is diagnosed, and caregivers, patients, and their families could plan on a median life span as long as 7 to 10 years for patients whose conditions are diagnosed when they are in their 60s and early 70s, to only about 3 years or less for patientswhose conditions are Diagnoses of AD at ages 65 and 90 years.

Epidemiology of Alzheimer disease

An overview of the criteria used in the diagnosis of Alzheimer disease is provided, highlighting how this disease is related to, but distinct from, normal aging.